Subsidiary FarmPharma raised more than SEK 2 million through a targeted share issue
The Board of FarmPharma has now, with the support of the authorization received at the extraordinary general meeting on November 19, 2018, implemented a directed new issue of a total of 2 145 470 SEK. The issue is directed at private and institutional investors and is expected to be registered within 3 weeks. Issue costs consist only of registration costs for the issue. Double Bond Pharmaceuticals ownership part is thereby reduced from 92% till 76%.
"We see a great need in the community for FarmPharma products, both from sustainability and environmental perspectives. - says on Igor Lokot, CEO of Double Bond Pharmaceutical and Chairman of the board for FarmPharma, - The ongoing new share issue raises cash to maintain the high pace of development of the company "
More om FarmPharma: FarmPharma AB is a subsidiary of Double Bond Pharmaceutical. The company is active in the development and distribution of veterinary products, and their first product is for the prevention and treatment of bacterial and viral infections in cattle without the use of antibiotics. For more info: http://www.farmpharma.se/
Video presentation: https://youtu.be/e1cPSC2PC70
This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 16 of January 2018.
For more info, contact
Igor Lokot, CEO
Homepage: http://www.doublebp.com/
E-mail: info@doublebp.com
Blog: http://blog.doublebp.com
Follow us on LinkedIn, Facebook and Twitter!
Information on Double Bond Pharmaceutical International AB
DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline. DBP has during the past year also started two subsidiaries, Drugsson AB for the distribution of fully developed human pharmaceutical and medical device products and dietary supplements in Scandinavia, and FarmPharma AB for the development of innovative veterinary products.
Tags: